Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2021 | PET2-assoicated outcomes in patients with DLBCL

Sanjal Desai • 12 Dec 2021

ASH 2021

Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma R-CHOP

Conflicting data exists on the association between positron emission tomography scans after 2 cycles of therapy (PET2) and survival rates in patients with diffuse large B-cell lymphoma (DLBCL) who progress after rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, investigates the impact of PET2 on survival in patients with DLBCL. Patients from a Phase II trial (NCT00670358) and the Mayo Clinic Molecular Epidemiology Resource were included in the analysis. Patients who are PET2-postive were found to have inferior overall survival and progression-free survival rates. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Hodgkin lymphoma: prognostic markers in the era of novel treatments

Sanjal Desai • 19 Jun 2023

Impact of checkpoint inhibitor-based salvage regimens prior to alloSCT in R/R cHL

Sanjal Desai • 19 Jun 2023

Overall survival in patients with cHL who progress after autoSCT in the era of novel agents

Sanjal Desai • 19 Jun 2023

Patient selection for autoSCT in HL & increasing CR rate before autoSCT with novel salvage regimens

Sanjal Desai • 21 Feb 2023

Related Videos

Promising novel immunotherapeutic approaches in lymphoma

Gloria Iacoboni • 15 Apr 2024

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024

Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL

Jacopo Mariotti • 15 Apr 2024

Exciting CAR-T clinical trials in LBCL and FL

Gloria Iacoboni • 15 Apr 2024